Market accessOfficial

Denmark updates import window for estradiol 25 microgram patches in supply failure

🇩🇰 DKMA · Fri 13 Nov 2026

The Danish Medicines Agency has revised the expected period during which a foreign estradiol 25 micrograms/24 hours depot patch can be supplied under section 29(2) of the Medicines Act.

The Danish Medicines Agency (DKMA) has updated the time period for an estradiol medicine on its list of products in supply failure. For this product, the agency wants the Danish market supplied with a corresponding foreign-market medicine under section 29(2) of the Danish Medicines Act.

The entry covers estradiol as depot patches, 25 micrograms/24 hours, ATC code G03CA03, for human use. The expected period is mid-May to the end of December 2026. The page was first published on 24 April 2026 and updated on 13 November 2026.

A remark on the entry notes a larger delivery in mid-September 2026. The source does not explain how that delivery relates to the end-December date, and it gives no further detail on the cause or scale of the shortage.

DKMA says the expected period for needing foreign packs may change over time. It will update the entry based on information received from the marketing authorisation holders. The full list and further information on selling foreign packs under section 29(2) are on a separate DKMA page for pharmaceutical companies.

What it means for your team

  • Danish marketing authorisation holders and suppliers should treat mid-May to end-December 2026 as the current window for supplying the foreign estradiol 25 micrograms/24 hours patch under section 29(2).
  • The window is provisional. DKMA bases changes on information from marketing authorisation holders, so timely supply updates to the agency matter.
  • Supply and market-access teams should check the main DKMA list of foreign alternatives for conditions on selling foreign packs, as this entry does not set them out.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Market access All →